Gemphire Therapeutics (GEMP) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Gemphire Therapeutics (NASDAQ:GEMP) from a hold rating to a sell rating in a report issued on Wednesday morning.

According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “

A number of other equities research analysts have also recently weighed in on GEMP. HC Wainwright reaffirmed a buy rating and set a $22.00 price target (up from $21.00) on shares of Gemphire Therapeutics in a report on Tuesday, November 14th. Canaccord Genuity reaffirmed a buy rating on shares of Gemphire Therapeutics in a report on Friday, October 13th. Roth Capital began coverage on Gemphire Therapeutics in a report on Thursday, October 19th. They set a buy rating and a $30.00 price target for the company. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $22.00 price target on shares of Gemphire Therapeutics in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $22.17.

Gemphire Therapeutics (NASDAQ GEMP) traded up $0.25 during mid-day trading on Wednesday, reaching $8.17. The company had a trading volume of 53,494 shares, compared to its average volume of 37,587. Gemphire Therapeutics has a 12-month low of $6.61 and a 12-month high of $21.59. The firm has a market cap of $84.21, a PE ratio of -2.42 and a beta of 3.07. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.14). equities research analysts forecast that Gemphire Therapeutics will post -3.31 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Comerica Bank bought a new position in Gemphire Therapeutics in the 3rd quarter valued at $850,000. Northpointe Capital LLC boosted its position in shares of Gemphire Therapeutics by 91.8% in the 3rd quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock worth $4,943,000 after purchasing an additional 249,077 shares during the last quarter. GM Advisory Group Inc. bought a new position in shares of Gemphire Therapeutics in the 2nd quarter worth $457,000. Bamco Inc. NY bought a new position in shares of Gemphire Therapeutics in the 3rd quarter worth $2,709,000. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of Gemphire Therapeutics by 4.5% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock worth $1,520,000 after purchasing an additional 6,900 shares during the last quarter. Hedge funds and other institutional investors own 32.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.com-unik.info/2018/01/20/gemphire-therapeutics-gemp-stock-rating-lowered-by-zacks-investment-research.html.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit